New Mexico Register / Volume XXXI, Issue 12 / June 23, 2020
This is an
amendment to 7.34.2 NMAC, Section 7 effective 6/23/2020.
7.34.2.7 DEFINITIONS:
[ A. “Act” means the Lynn and Erin Compassionate Use Act, NMSA 1978, Sections 26-2B-1 through 26-2B-7.
B. “Adequate
supply” means an amount of cannabis, derived solely from an intrastate source and in
a form approved by the department, that is possessed by a qualified patient or
collectively possessed by a qualified patient and the qualified patient’s
primary caregiver, that is determined by the department to be no more than
reasonably necessary to ensure the uninterrupted
availability of cannabis for a period of three months or 90 consecutive
calendar days.
C. “Administrative review committee” means
an intra-department committee that reviews qualified patient or primary
caregiver application denials, licensed producer denials made by the program
manager, or the summary suspension of a producer’s license, in accordance with
department rules. The administrative
review committee shall consist of the chief medical officer of the department
(or that’s person’s designee); a deputy secretary of the department (or that
person’s designee), and the chief nursing officer of the department (or that
person’s designee).
D. “Administrative
withdrawal” means the procedure for the voluntary withdrawal of a
qualified patient or primary caregiver from the medical cannabis program.
E. “Advisory
board” means the medical
cannabis advisory board consisting of nine practitioners knowledgeable about the medical use of cannabis, who are appointed
by the secretary.
F. “Applicant”
means any person applying for enrollment or re-enrollment in the medical
cannabis program as a qualified patient,
primary caregiver, or licensed producer.
G. “Approved
laboratory” means a licensed cannabis testing facility as defined in the
Lynn and Erin Compassionate Use Act, Subsection I of Section 26-2B-3 NMSA 1978
that has been approved by the department
specifically for the testing of cannabis, concentrates, and cannabis derived
products.
H. “Batch”
means, with regard to usable cannabis, a homogenous, identified quantity of
cannabis no greater than five pounds that is harvested during a specified time
period from a specified cultivation area, and with regard to concentrated and
cannabis-derived product, means an identified quantity that is uniform, that is
intended to meet specifications for identity, strength, and composition, and
that is manufactured, packaged, and labeled during a specified time period
according to a single manufacturing, packaging, and labeling protocol.
I. “Cannabidiol
(“CBD”)” is a cannabinoid and the primary non-psychoactive ingredient found
in cannabis.
J. “Cannabis”
means all parts of the plant Cannabis sativa L. containing a
delta-9-tetrahydrocannabinol concentration of more than three-tenths percent on
a dry weight basis, whether growing or not; the seeds of the plant; the resin
extracted from any part of the plant; and every compound, manufacture, salt,
derivative, mixture or preparation of the plant, its seeds or its resin; and
does not include the mature stalks of the plant; fiber produced from the
stalks; oil or cake made from the seeds of the plant; any other compound,
manufacture, salt, derivative, mixture or preparation of the mature stalks,
fiber, oil or cake; the sterilized seed of the plant that is incapable of
germination; the weight of any other ingredient combined with cannabis to
prepare topical or oral administrations, food, drink or another product; or
hemp.
K. “Cannabis-derived product” means a product, other than cannabis itself, which contains or is
derived from cannabis, not including hemp.
L. “Concentrated
cannabis-derived product (“concentrate”)” means a cannabis-derived product
that is manufactured by a mechanical or chemical process that separates any
cannabinoid from the cannabis plant, and that contains (or that is intended to
contain at the time of sale or distribution) no less than thirty-percent (30%) THC by weight.
M. “Courier” means a person or entity that
transports usable cannabis within the state of New Mexico from a licensed
non-profit producer to a qualified patient or primary caregiver, to another
non-profit producer, to an approved laboratory, or to an approved manufacturer.
N. “Debilitating
medical condition” means:
(1) cancer;
(2) glaucoma;
(3) multiple
sclerosis;
(4) damage
to the nervous tissue of the spinal cord, with objective neurological indication of intractable spasticity;
(5) epilepsy;
(6) positive
status for human immunodeficiency virus or acquired immune deficiency syndrome;
(7) admission
into hospice care in accordance
with rules promulgated by the department;
(8) amyotrophic
lateral sclerosis;
(9) Crohn’s
disease;
(10) hepatitis C infection;
(11) Huntington’s
disease;
(12) inclusion body myositis;
(13) inflammatory autoimmune-mediated arthritis;
(14) intractable nausea or vomiting;
(15) obstructive sleep apnea;
(16) painful peripheral neuropathy;
(17) Parkinson’s
disease;
(18) posttraumatic stress disorder;
(19) severe chronic pain;
(20) severe anorexia or cachexia;
(21) spasmodic torticollis;
(22) ulcerative colitis; or
(23) any other medical condition, medical treatment, or disease
as approved by the department which results in pain, suffering, or debility for
which there is credible evidence that medical
use cannabis could be of benefit.
O. “Department”
means the department of health or its agent.
P. “Facility” means any
building, space, or grounds licensed for the production, possession, testing,
manufacturing, or distribution of cannabis, concentrates, or cannabis-derived
products.
Q. “Intrastate”
means existing or occurring within the state boundaries of New Mexico.
R. “Laboratory applicant” means a
laboratory that seeks to become an approved laboratory, or that seeks renewal
of approval as an approved laboratory, in accordance with this rule.
S. “License” means the document issued by the department granting the legal right to
produce medical cannabis for a specified period of time.
T. “Licensed
producer” means a person or entity licensed to produce medical
cannabis.
U. “Licensure” means the process by which the department grants permission to an applicant to
produce cannabis.
V. “Lot”
means an identified portion of a batch, that is uniform and that is intended to
meet specifications for identity, strength, and composition; or, in the case of
a cannabis-derived product or concentrate, an identified quantity produced in a
specified period of time in a manner that is uniform and that is intended to
meet specifications for identity, strength, and composition.
W. “Male plant” means a
male cannabis plant.
X. “Manufacture”
means to make or otherwise produce cannabis-derived product or concentrate.
Y. “Manufacturer”
means a person that is licensed by the department to manufacture cannabis
products; package, transport or courier cannabis products; have cannabis
products tested by a cannabis testing facility; purchase, obtain, sell and
transport cannabis products to other cannabis establishments; and prepare
products for personal production license holders.
Z. “Mature
female plant” means a harvestable female cannabis
plant that is flowering.
AA. “Medical cannabis program”
means the administrative body of the department charged with the management of the medical cannabis program and
enforcement of program regulations, to include issuance of registry
identification cards, licensing of producers, and regulation of manufacturing
and distribution.
BB. “Medical cannabis program manager”
means the administrator of the medical cannabis program who holds that title.
CC. “Medical
director” means a medical practitioner designated by the department to determine whether the medical condition of an
applicant qualifies as a debilitating medical condition eligible for enrollment
in the program, and to perform other duties.
DD. “Medical
provider certification for patient eligibility form” means a written
certification form provided by the medical cannabis
program signed by a patient's practitioner that, in the practitioner's
professional opinion, the patient has a debilitating medical condition as
defined by the act or this part and would be anticipated to benefit from the
use of cannabis.
EE. “Minor” means an
individual less than 18 years of age.
FF. “Non-profit
producer” means a New Mexico corporation that has been designated as a
non-profit corporation by the New Mexico Secretary of State, that has been
licensed by the department to possess, produce, dispense, distribute and
manufacture cannabis and cannabis products and sell wholesale or by direct sale
to qualified patients and primary caregivers.
GG. “Paraphernalia”
means any equipment, product, or material of any kind that is primarily
intended or designed for use in compounding, converting, processing, preparing, inhaling, or otherwise introducing cannabis or its
derivatives into the human body.
HH. “Patient
enrollment/re-enrollment form” means the registry identification
card application form for patient applicants provided by the medical cannabis
program.
II. “Personal production license” means a license issued to a qualified patient or to a qualified patient’s
primary caregiver participating in the medical cannabis program to permit the
qualified patient or the qualified patient's primary caregiver to produce
cannabis for the qualified patient's use at an address approved by the
department.
JJ. “Petitioner”
means any New Mexico resident or association of New Mexico residents
petitioning the advisory board for the inclusion of a new medical condition, medical treatment, or disease to be added to the list of debilitating medical conditions
that qualify for the use of cannabis.
KK. “Plant”
means any cannabis plant, cutting, or clone that has roots or that is
cultivated with the intention of growing roots.
LL. “Policy” means a written statement of principles
that guides and determines present and future decisions and actions of the
licensed producer.
MM. “Practitioner”
means a person licensed in New Mexico to prescribe and administer drugs that
are subject to the Controlled Substances
Act, Sections 30-31-1 et
seq., NMSA 1978.
NN. “Primary caregiver” means a resident of New Mexico who is at least 18 years of age
and who has been designated by the qualified patient or their representative
and the patient’s practitioner as being necessary to take responsibility for managing the well-being of a qualified
patient with respect to the medical use of cannabis pursuant to the provisions
of the Lynn and Erin Compassionate Use Act, Section 26-2B-1 et seq., NMSA 1978.
OO. “Primary
caregiver application form” means the registry identification card
application form provided by the medical cannabis program.
PP. “Private
entity” means a private,
non-profit organization that applies to become or is licensed as a producer and
distributor of cannabis, concentrates, or cannabis-derived products.
QQ. “Proficiency
testing” means testing conducted by the department or its agent to
determine the ability of a laboratory applicant or approved laboratory to
accurately identify presence, quantity, or other factors pertaining to a given analyte.
RR. “Qualified
patient” means a resident of New Mexico who has been diagnosed by a
practitioner as having a debilitating medical condition and has received a
registry identification card issued pursuant to the requirements of the act or
department rules.
SS. “Registry
identification card” means
a document issued and owned by the department which identifies a qualified
patient authorized to engage in the use of cannabis for a debilitating medical
condition or a document issued by the department which identifies a primary caregiver authorized to engage in the intrastate possession and
administration of cannabis for the sole use of the qualified patient.
TT. “Representative”
means an individual designated as the applicant’s or petitioner’s agent,
guardian, surrogate, or other legally appointed
or authorized health care decision maker.
UU. “Secretary”
means the secretary of the New Mexico department of health.
VV. “Secure grounds” means a
facility that provides a safe environment to avoid
loss or theft.
WW. “Security
alarm system” means any device or series of devices capable of
alerting law enforcement , including, but not limited to, a signal system
interconnected with a radio frequency method such as cellular, private radio
signals, or other mechanical or electronic device
used to detect or report an emergency or unauthorized intrusion.
XX. “Security policy” means
the instruction manual or pamphlet adopted or developed by the licensed
producer containing security policies, safety and security procedures, and personal safety and crime prevention techniques.
YY. “Seedling”
means a cannabis plant that has no flowers and that is less than 12 inches
in height, as measured vertically in the plant’s natural position from the
uppermost part of the root system (or from the soil line, if the plant is
planted in soil) to the tallest point of the plant.
ZZ. “Segregate” means to separate and
withhold from use or sale batches, lots, cannabis, usable cannabis, or
cannabis-derived products in order to first determine its suitability for use
through testing by an approved laboratory.
AAA. “THC” means tetrahydrocannabinol, a cannabinoid that is the primary
psychoactive ingredient in cannabis.
BBB. “Technical evidence” means scientific,
clinical, medical, or other specialized testimony, or evidence, but does not
include legal argument, general comments, or statements of policy or position
concerning matters at issue in the hearing.
CCC. “Telemedicine” means the use of
telecommunications and information technology to provide clinical health care
from a site apart from the site where the patient is located, in real time or
asynchronously,
including the use of interactive simultaneous audio and video or
store-and-forward technology, or off-site patient
monitoring and telecommunications in order to deliver health care services.
DDD. “Testing” means the process and procedures provided by an approved
laboratory for testing of cannabis and cannabis derived products, consistent
with provisions of this rule.
EEE. “Unit”
means a quantity of usable cannabis, concentrate, or cannabis-derived product
that is used in identifying the maximum supply that a qualified patient may
possess for purposes of department rules.
FFF. “Usable
cannabis” means the dried leaves and flowers of the female cannabis
plant and cannabis-derived products, including concentrates, but does not
include the seeds, stalks, or roots of the
plant.]
A. Definitions
beginning with “A”:
(1) “Act” means the Lynn and Erin Compassionate Use Act, 26-2B-1
through 26-2B-10, NMSA 1978.
(2) “Adequate supply” means
an amount of cannabis, in a form approved by the department possessed by a
qualified patient or collectively possessed by a qualified patient and the
qualified patient’s primary caregiver, that is determined by rule of the
department to be no more than reasonably necessary to ensure the uninterrupted availability of cannabis for a
period of three months and that is derived solely from an intrastate source.
(3) “Administrative review committee” means
an intra-department committee that reviews qualified patient or primary
caregiver application denials, licensed producer denials made by the program director,
or the summary suspension of a producer’s license, in accordance with
department rules. The administrative
review committee shall consist of the chief medical officer of the department
(or that’s person’s designee); a deputy secretary of the department (or that
person’s designee), and the chief nursing officer of the department (or that
person’s designee).
(4) “Administrative withdrawal”
means the procedure for the voluntary withdrawal of a qualified patient or
primary caregiver from the medical cannabis program.
(5) “Advisory board” means
the medical cannabis advisory board
consisting of nine practitioners
knowledgeable about the medical use of cannabis, who are appointed by the
secretary.
(6) “Applicant” means any
person applying for enrollment or re-enrollment in the medical cannabis program
as a qualified patient, primary
caregiver, or licensed producer.
(7) “Approved entity” means a manufacturer,
laboratory, or courier.
B. Definitions
beginning with “B”: “Batch” means, with regard to usable cannabis, an identified quantity of
cannabis no greater than five pounds that is of the same strain of cannabis,
that is harvested during the same specified time period from the same specified
cultivation area, and with respect to which he same agricultural practices were
utilized, including the use of any pesticides; and with regard to concentrated
and cannabis-derived product, means an identified quantity that is uniform,
that is intended to meet specifications for identity, strength, and
composition, and that is manufactured, packaged, and labeled during a specified
time period according to a single manufacturing, packaging, and labeling
protocol.
C. Definitions
beginning with “C”:
(1) “Cannabis” means all parts of the plant Cannabis sativa L. containing
a delta-9-tetrahydrocannabinol concentration of more than three-tenths percent
on a dry weight basis, whether growing or not; the seeds of the plant; the
resin extracted from any part of the plant; and every compound, manufacture,
salt, derivative, mixture or preparation of the plant, its seeds or its resin;
and does not include the mature stalks of the plant; fiber produced from the
stalks; oil or cake made from the seeds of the plant; any other compound,
manufacture, salt, derivative, mixture or preparation of the mature stalks,
fiber, oil or cake; the sterilized seed of the plant that is incapable of
germination; the weight of any other ingredient combined with cannabis to
prepare topical or oral administrations, food, drink or another product; or
hemp.
(2) “Cannabis consumption area” means an area within a licensed
nonprofit producer’s premises that is approved by the department, where
cannabis may be consumed by qualified patients, in accordance with department
rules;
(3) “Cannabis-derived product” means a product, other than cannabis itself, which contains or is
derived from cannabis, not including hemp.
(4) “Cannabis establishment” means:
(a) a licensed cannabis courier;
(b) a licensed cannabis testing facility;
(c) a licensed cannabis manufacturer;
(d) a licensed non-profit producer; or
(e) such other person that the department may by rule approve
for participation in the medical cannabis program;
(5) “CBD” means cannabidiol, a cannabinoid and the
primary non-psychoactive ingredient found in cannabis.
(6) “CBDA” means cannabidiolic acid, a
non-psychoactive ingredient found in cannabis and an acid precursor to CBD.
(7) “Concentrated
cannabis-derived product (“concentrate”)” means a cannabis-derived product
that is manufactured by a mechanical or chemical process that separates any
cannabinoid from the cannabis plant, and that contains (or that is intended to
contain at the time of sale or distribution) no less than thirty-percent THC by
weight.
(8) “Courier” means a cannabis courier as
defined by the Lynn and Erin Compassionate Use Act, Subsection D of Section
26-2b-3 NMSA 1978, that has been approved by the
department specifically to transport usable cannabis and cannabis products within
the state of New Mexico from a cannabis establishment to a qualified patient, a
primary caregiver, or another cannabis establishment.
D. Definitions beginning with “D”:
(1) “Debilitating medical condition” means:
(a) cancer;
(b) glaucoma;
(c) multiple sclerosis;
(d) damage to the nervous tissue
of the spinal cord, with objective neurological indication of intractable spasticity;
(e) epilepsy;
(f) positive status for human
immunodeficiency virus or acquired immune deficiency syndrome;
(g) admission into hospice care
in accordance with rules promulgated by the
department;
(h) amyotrophic lateral sclerosis;
(i) Crohn’s
disease;
(j) hepatitis C
infection;
(k) Huntington’s disease;
(l) inclusion
body myositis;
(m) inflammatory
autoimmune-mediated arthritis;
(n) intractable
nausea or vomiting;
(o) obstructive
sleep apnea;
(p) painful
peripheral neuropathy;
(q) Parkinson’s disease;
(r) posttraumatic
stress disorder;
(s) severe
chronic pain;
(t) severe
anorexia or cachexia;
(u) spasmodic
torticollis;
(v) ulcerative
colitis; or
(w) any other
medical condition, medical treatment, or disease as approved by the department
which results in pain, suffering, or debility for which there is credible evidence
that medical use cannabis could be of benefit.
(2) “Department”
means the department of health or its agent.
(3) “Diversion” means the unlawful transfer
of a cannabis plant, plant material, or cannabis-derived product.
(4) “Dried usable cannabis” means the dried leaves, flowers, and trim of the female
cannabis plant, but does not include the seeds, stalks, or roots of the
cannabis plant.
E. Definitions beginning with “E”: [RESERVED]
F. Definitions beginning with “F”: “Facility” means any building, space, or grounds licensed for the
production, possession, testing, manufacturing, or distribution of cannabis,
concentrates, or cannabis-derived products.
G. Definitions
beginning with “G”: [RESERVED]
H. Definitions
beginning with “H”: “Hemp”
means the plant cannabis sativa L. and any part of the plant, whether growing
or not, containing a delta-9-tetrahydrocannabinol concentration of no more than
three-tenths percent on a dry weight basis.
I. Definitions
beginning with “I”:
(1) “Intrastate” means existing or occurring within the state boundaries of
New Mexico.
(2) “Inversion” means the unlawful acquisition of a cannabis plant, plant
material, or cannabis-derived product.
J. Definitions beginning with “J”: [RESERVED]
K. Definitions
beginning with “K”: [RESERVED]
L. Definitions
beginning with “L”:
(1) “Laboratory” means a licensed cannabis testing facility as defined in the Lynn and
Erin Compassionate Use Act, Subsection I of Section 26-2B-3 NMSA 1978, that has
been approved by the department specifically for the testing of cannabis, concentrates, and cannabis derived products.
(2) “Laboratory
applicant” means a laboratory that seeks to become an approved laboratory,
or that seeks renewal of approval as an approved laboratory, in accordance with
this rule.
(3) “Licensed producer”
means a person or entity licensed to produce medical cannabis.
(4) “Lot” means
an identified portion of a batch, that is uniform and that is intended to meet
specifications for identity, strength, and composition; or, in the case of a
cannabis-derived product or concentrate, an identified quantity produced in a
specified period of time in a manner that is uniform and that is intended to
meet specifications for identity, strength, and composition.
M. Definitions
beginning with “M”:
(1) “Male plant” means a male cannabis plant.
(2) “Manufacture” means to prepare a cannabis.
(3) “Manufacturer” means a cannabis
manufacturer as defined in the Lynn and Erin Compassionate Use Act, Subsection
F of Section 26-2B-3 NMSA 1978, that has been approved by the department specifically
to manufacture cannabis products; package, transport or courier cannabis
products; have cannabis products tested by a cannabis testing facility;
purchase, obtain, sell and transport cannabis products to other cannabis
establishments; and prepare products for personal production license holders.
(4) “Mature female plant” means a harvestable female cannabis plant that is
flowering.
(5) “Medical cannabis program”
means the administrative body of the department charged with the management of the medical cannabis program and
enforcement of program regulations, to include issuance of registry
identification cards, licensing of producers, and regulation of manufacturing
and distribution.
(6) “Medical cannabis program director”
means the administrator of the medical cannabis program who holds that title.
(7) “Medical director” means a
medical practitioner designated by the
department to determine whether the medical condition of an applicant qualifies
as a debilitating medical condition eligible for enrollment in the program, and
to perform other duties.
(8) “Medical provider certification for
patient eligibility form” means a written certification form provided by the medical cannabis program signed by a
patient's practitioner that, in the practitioner's professional opinion, the
patient has a debilitating medical condition as defined by the act or this part
and would be anticipated to benefit from the use of cannabis.
(9) “Minor” means an
individual who is less than 18 years of age.
N. Definitions beginning with “N”: “Non-profit
producer” means a New Mexico corporation that has been designated as a
non-profit corporation by the New Mexico secretary of state,
that has been licensed by the department to possess, produce, dispense,
distribute and manufacture cannabis and cannabis products and sell wholesale or
by direct sale to qualified patients and primary caregivers.
O. Definitions
beginning with “O”: [RESERVED]
P. Definitions beginning with “P”:
(1) “Paraphernalia” means any equipment, product, or material of any kind that
is primarily intended or designed for use in compounding, converting,
processing, preparing, inhaling, or otherwise introducing
cannabis or its derivatives into the human body.
(2) “Patient enrollment/re-enrollment
form” means the registry identification card application form for
patient applicants provided by the medical cannabis program.
(3) “Permanent structure” means a building
or structure that is placed on the land for the foreseeable future that is
anchored to a permanent foundation, that is roofed and walled, and which
requires a building permit from a local and or state governing authority.
(4) “Personal production license” means a license
issued to a qualified patient or to a qualified patient’s primary caregiver
participating in the medical cannabis program to permit the qualified patient
or the qualified patient's primary caregiver to produce cannabis for the
qualified patient's use at an address approved by the department.
(5) “Pesticide” means a pesticide as defined by the New Mexico Pesticide
Control Act, Section 76-4-3, NMSA 1978.
(6) “Petitioner” means any New Mexico resident or association of
New Mexico residents petitioning the advisory board for the inclusion of a new medical condition, medical treatment, or disease to be added to the list of debilitating medical conditions
that qualify for the use of cannabis.
(7) “Plant”
means any cannabis plant, cutting, or clone that has roots or that is
cultivated with the intention of growing roots.
(8) “Policy” means a written statement of principles that guides and
determines present and future decisions and actions of the licensed producer.
(9) “Practitioner”
means a person licensed in New Mexico to prescribe and administer drugs that
are subject to the Controlled Substances
Act, Sections 30-31-1 et
seq., NMSA 1978.
(10) “Primary caregiver” means a resident of New Mexico who is at least 18 years of age
and who has been designated by the qualified patient or their representative
and the patient’s practitioner as being necessary to take responsibility for managing the well-being of a qualified patient
with respect to the medical use of cannabis pursuant to the provisions of the
Lynn and Erin Compassionate Use Act, Section 26-2B-1 et seq., NMSA 1978.
(11) “Primary
caregiver application form” means the registry identification card
application form provided by the medical cannabis program.
(12) “Private entity” means a private, non-profit organization that applies to become
or is licensed as a producer and distributor of cannabis, concentrates, or
cannabis-derived products.
(13) “Produce” means to engage in any
activity related to the planting or cultivation of cannabis.
(14) “Proficiency testing”
means testing conducted by the department or its agent to determine the ability
of a laboratory applicant or approved laboratory to accurately identify
presence, quantity, or other factors pertaining to a given analyte.
Q. Definitions beginning with “Q”: “Qualified
patient” means a resident of New Mexico who has been diagnosed by a
practitioner as having a debilitating medical condition and has received a
registry identification card issued pursuant to the requirements of the act or
department rules.
R. Definitions
beginning with “R”:
(1) “Recall” means to request the return of
a product after the discovery of a safety issue or product defect.
(2) “Reciprocal limit” means the quantity
of cannabis and cannabis products that a reciprocal participant can use and
possess in a given year pursuant to department rule.
(3) “Reciprocal participant” means an
individual who holds proof of authorization to participate in the medical
cannabis program of another state of the United States, the District of
Columbia, a territory or commonwealth of the United States or a New Mexico
Indian nation, tribe or pueblo.
(4) “Registry identification card” means a document issued and owned by the
department which identifies a qualified patient authorized to engage in the use
of cannabis for a debilitating medical condition or a document issued by the
department which identifies a primary
caregiver authorized to engage in the intrastate possession and administration
of cannabis for the sole use of the qualified patient.
(5) “Representative” means an
individual designated as the applicant’s or petitioner’s agent, guardian,
surrogate, or other legally
appointed or authorized health care decision maker.
S. Definitions
beginning with “S”:
(1) “Secretary” means the secretary of the New Mexico department of health.
(2) “Secure
grounds” means a facility that
provides a safe environment to avoid loss or theft.
(3) “Security alarm system” means
any device or series of devices capable of alerting law enforcement ,
including, but not limited to, a signal system interconnected with a radio
frequency method such as cellular, private radio signals, or other mechanical or electronic device used to detect or report
an emergency or unauthorized intrusion.
(4) “Security policy” means the
instruction manual or pamphlet adopted or developed by the licensed producer
containing security policies, safety and security procedures, and personal safety and crime prevention techniques.
(5) “Seedling” means a cannabis plant
that has no flowers and that is less than 12 inches in height, as measured
vertically in the plant’s natural position from the uppermost part of the root
system (or from the soil line, if the plant is planted in soil) to the tallest
point of the plant.
(6) “Segregate”
means to separate and withhold from use or sale batches, lots, cannabis, usable
cannabis, or cannabis-derived products in order to first determine its
suitability for use through testing by an approved laboratory.
T. Definitions beginning
with “T”:
(1) “THC” means tetrahydrocannabinol, a cannabinoid that is the primary
psychoactive ingredient in cannabis.
(2) “THCA” means tetrahydrocannabinolic acid, a
non-psychoactive ingredient in cannabis and an acid precursor to THC.
(3) “Technical evidence” means scientific,
clinical, medical, or other specialized testimony, or evidence, but does not
include legal argument, general comments, or statements of policy or position
concerning matters at issue in the hearing.
(4) “Telemedicine”
means the use of telecommunications and information technology to provide
clinical health care from a site apart from the site where the patient is
located, in real time or asynchronously, including the use of interactive
simultaneous audio and video or store-and-forward technology, or off-site
patient monitoring and telecommunications in order to deliver health care
services.
(5) “Testing” means testing of cannabis and cannabis derived products,
consistent with provisions of this rule.
U. Definitions beginning with “U”:
(1) “Unit” means a quantity of usable cannabis, concentrate, or cannabis-derived
product that is used in identifying the maximum supply that a qualified patient
may possess for purposes of department rules.
(2) “Usable
cannabis” means the dried leaves and flowers of the female cannabis
plant and cannabis-derived products, including concentrates, but does not
include the seeds, stalks, or roots of the
plant.
V. Definitions beginning with “V”: [RESERVED]
W. Definitions beginning with “W”:
“Wastage” means the destruction of usable
cannabis or cannabis plants.
X. Definitions
beginning with “X”: [RESERVED]
Y. Definitions beginning with “Y”:
Z. Definitions beginning with “Z” [RESERVED]
[7.34.2.7 NMAC - Rp,
7.34.2.7 NMAC, 2/27/2015; A, 2/29/2016;
A, 8/27/2019; A, 6/23/2020]